Spyre Therapeutics CEO Cameron Turtle sells $1.3m in shares

Cameron Turtle, CEO and Director of Spyre Therapeutics, sold 15,000 shares of the company's stock on September 1st, 2026, for a total value of $1,309,410. The sales took place at various prices, with 2,500 shares going for $86.36, 8,400 shares for $87.15, 3,700 shares for $88.06, and the remaining 400 shares at $89.07 per share.

These transactions were executed under a pre-approved Rule 10b5-1 trading plan. This move comes after the company's shares had a remarkable 414% increase over the past year, although the stock is currently deemed overvalued according to InvestingPro's Fair Value analysis. After these sales, Mr. Turtle remains a significant holder of the company's stock, now owning 552,540 shares, which includes shares scheduled to vest over the next year contingent upon his continued service.

Further to this, Spyre Therapeutics shared topline results from its Phase II SKYWAY-RA program, which assessed the effectiveness of SPY072/TL1A in treating rheumatoid arthritis. The results indicated statistically significant improvement over placebo, but the effect size did not meet the company's threshold for prioritizing monotherapy development.

Despite this, both Guggenheim and Stifel maintained a Buy rating on the company, setting price targets of $130 and $123 respectively. However, Wolfe Research downgraded Spyre Therapeutics to Peerperform from Outperform, citing valuation concerns. On a more optimistic note, Mizuho raised its price target for Spyre Therapeutics shares to $120, buoyed by promising data from the SKYLINE Part A study for SPY001 and SPY002, suggesting high potential for clinical remission rates.

This story presents a complex picture of Spyre Therapeutics, with various analysts holding differing views on the company's future.